In vitro pharmacodynamics of nemonoxacin and other antimicrobial agents against Mycoplasma pneumoniae

Na Wang; Yuancheng Chen; Xingyi Qu; Xingchen Bian; Jiali Hu; Xiaogang Xu; Li Xiao; Yang Liu; Jing Zhang

doi:10.1128/spectrum.02431-23

Microbiology Spectrum (Dec 2023)

In vitro pharmacodynamics of nemonoxacin and other antimicrobial agents against Mycoplasma pneumoniae

Na Wang,
Yuancheng Chen,
Xingyi Qu,
Xingchen Bian,
Jiali Hu,
Xiaogang Xu,
Li Xiao,
Yang Liu,
Jing Zhang

Affiliations

Na Wang: Institute of Antibiotics, Huashan Hospital, Fudan University , Shanghai, China
Yuancheng Chen: Institute of Antibiotics, Huashan Hospital, Fudan University , Shanghai, China
Xingyi Qu: Institute of Antibiotics, Huashan Hospital, Fudan University , Shanghai, China
Xingchen Bian: Institute of Antibiotics, Huashan Hospital, Fudan University , Shanghai, China
Jiali Hu: Institute of Antibiotics, Huashan Hospital, Fudan University , Shanghai, China
Xiaogang Xu: Institute of Antibiotics, Huashan Hospital, Fudan University , Shanghai, China
Li Xiao: Department of Medicine, University of Alabama at Birmingham , Birmingham, Alabama, USA
Yang Liu: Institute of Antibiotics, Huashan Hospital, Fudan University , Shanghai, China
Jing Zhang: Institute of Antibiotics, Huashan Hospital, Fudan University , Shanghai, China

DOI: https://doi.org/10.1128/spectrum.02431-23
Journal volume & issue: Vol. 11, no. 6

Abstract

Read online

ABSTRACT Mycoplasma pneumoniae is the causative agent of respiratory infections in children and adults. Macrolide still plays a significant role in treating infections by M. pneumoniae. However, macrolide-resistant M. pneumoniae (MRMP) was encountered, causing more severe or prolonged disease worldwide from the early 2000s. Nemonoxacin is a newly developed C-8-methoxy non-fluorinated quinolone having broad-spectrum activity against gram-positive, gram-negative, and atypical pathogens in vitro, as well as general safety and well tolerance in vivo. This study aimed to assess the killing kinetics of nemonoxacin and other antimicrobial agents against MRMP and macrolide susceptible M. pneumoniae (MSMP) by static time-kill curves. In addition, the pharmacodynamic analyses of these drugs were determined by the sigmoid E max model. The static time-kill curves indicated that nemonoxacin had good mycoplasmacidal activity against both MSMP and MRMP strains. The pharmacodynamic analysis demonstrated that the mycoplasmacidal effect of nemonoxacin was greater than those of moxifloxacin and levofloxacin based on the K max, displaying a dualism of concentration dependency in low minimum inhibitory concentrations (MICs) and time dependency in high MICs. Therefore, nemonoxacin demonstrated efficacy against M. pneumoniae in vitro and is a potential candidate for clinical studies for assessing its therapeutic effects against M. pneumoniae infections. The killing pattern or PK/PD characteristics of nemonoxacin against M. pneumoniae from in vitro data, animal studies, or clinical studies merit further evaluation for treating infections caused by the organism. IMPORTANCE This study first reported the in vitro effector kinetics of the new non-fluorinated quinolone, nemonoxacin, against macrolide-resistant M. pneumoniae (MRMP) and macrolide susceptible M. pneumoniae (MSMP) strains along with other antimicrobial agents. The time-kill assays and pharmacodynamic analysis showed that nemonoxacin has significant mycoplasmacidal activity against MRMP and MSMP. This study paves the road to establish appropriate dosing protocols of a new antimicrobial drug for children infected with M. pneumoniae.

Published in Microbiology Spectrum

ISSN: 2165-0497 (Online)
Publisher: American Society for Microbiology
Country of publisher: United States
LCC subjects: Science: Microbiology
Website: https://journals.asm.org/journal/spectrum

About the journal

Abstract

Keywords